XML 88 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)
Oct. 03, 2018
USD ($)
bundle
obligation
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Development, regulatory and sales milestones payments   $ 2,800,000,000  
Deferred revenue   866,000 $ 74,099,000
JJDC | Collaboration and License agreements      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Upfront payment $ 175,000,000    
JJDC | Common Stock Purchase Agreement | Collaboration and License agreements      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Proceeds from the sale of future royalties 75,000,000    
Janssen | Collaboration and License agreements      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Milestone payment $ 73,000,000    
Number of distinct bundle | bundle 1    
Number of distinct performance obligations | obligation 1    
Initial transaction price $ 252,700,000    
Janssen | Collaboration and License agreements | Maximum      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Development, regulatory and sales milestones payments 825,000,000    
Janssen | JNJ-3989 Agreement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Milestone payment $ 25,000,000    
Contract assets   0  
Deferred revenue   $ 0